Phosphatidylethanolamine at the Luminal Endothelial Surface—Implications for Hemostasis and Thrombotic Autoimmunity

Abstract

Objective: Accumulating evidence suggests that phosphatidylethanolamine (PE) is physically present at the luminal endothelial surface, where it tentatively functions as a critical anticoagulant. The goal of the current investigation was 3-fold: to characterize the distribution profile of PE at the luminal endothelial surface; to examine the immunoreactivity to the vascular endothelium by anti-PE (aPE) sera from patients presenting with thrombosis; and to discuss the potential mechanism of PE upregulation by endothelial cells. Methods: The rat aortic arch was selected as major conduit vessel under significant hemodynamic burden. The presence of PE and the antigenic profile of aPE sera at the luminal endothelial surface were examined using duramycin as a PEbinding probe and immunohistochemistry. Phosphatidylethanolamine upregulation at endothelial cell surface was investigated using cultured monolayer subject to laminar shear stress or thrombin treatment. Results: High levels of PE were detected at the luminal endothelial surface of aortic flow dividers, the ascending aorta, and the outer curvature of the aortic arch. The antigenic profiles of aPE sera, which are highly associated with elevated thrombotic risks in patients, are consistent with PE distribution along the endothelial surface. Finally, PE is upregulated at the surface of cultured endothelial cells in response to luminal shear stress but not thrombin. Conclusions: The current data describe the physical distribution of vascular PE at the blood—endothelium interface. The luminal PE presents a vulnerability to anti-PE autoimmunity and is consistent with the association between aPE and elevated risk for idiopathic thrombosis.

Keywords

phosphatidylethanolamine endothelium duramycin aPE thrombosis

References

Esmon NL , Smirnov MD , Safa O. , Esmon CT Lupus anticoagulants, thrombosis and the protein C system. Haematologica. 1999;84(5):446-451.

Sanmarco M.

Clinical significance of antiphosphatidylethanolamine antibodies in the so-called ‘‘seronegative antiphospholipid syndrome.’’

Autoimmun Rev. 2009 Mar 20. (Epub ahead of print).

Esmon NL , Smirnov MD , Esmon CT Thrombogenic mechanisms of antiphospholipid antibodies. Thromb Haemost. 1997;78(1): 79-82.

Smirnov MD , Triplett DT , Comp PC , Esmon NL , Esmon CT On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest. 1995;95(1):309-316.

Sanmarco M. , Gayet S. , Alessi MC , et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost. 2007;97(6):949-954.

Berard M. , Chantome R. , Marcelli A. , Boffa MC Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol. 1996;23(8):1369-1374.

Sanmarco M. , Alessi MC , Harle JR , et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost. 2001;85(5):800-805.

Boffa MC , Berard M. , Sugi T. , McIntyre JA Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity. J Rheumatol. 1996; 23(8):1375-1379.

Balada E. , Ordi-Ros J. , Paredes F. , Villarreal J. , Mauri M. , Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol. 2001;30(4):235-241.

10.

Sugi T. , Matsubayashi H. , Inomo A. , Dan L. , Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res. 2004;30(4):326-332.

11.

Sugi T. , Katsunuma J. , Izumi S. , McIntyre JA , Makino T. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril . 1999;71(6):1060-1065.

12.

Vinatier D. , Dufour P. , Cosson M. , Houpeau JL Antiphospholipid syndrome and recurrent miscarriages . Eur J Obstet Gynecol Reprod Biol. 2001;96(1):37-50.

13.

Tian Y. , Jackson P. , Gunter C. , Wang J. , Rock CO , Jackowski S. Placental thrombosis and spontaneous fetal death in mice deficient in ethanolamine kinase 2. J Biol Chem. 2006;281(38): 28438-28449.

14.

Smirnov MD , Safa O. , Regan L. , et al. A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J Biol Chem. 1998;273(15):9031-9040.

15.

Smirnov MD , Esmon CT Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem . 1994;269(2):816-819.

16.

Tsuda T. , Yoshimura H. , Hamasaki N. Effect of phosphatidylcholine, phosphatidylethanolamine and lysophosphatidylcholine on the activated factor X-prothrombin system. Blood Coagul Fibrinolysis. 2006;17(6):465-469.

17.

Li Z. , Wells CW , Esmon CT , Zhao M. Phosphatidylethanolamine at the endothelial surface of aortic flow dividers . J Thromb Haemost. 2009;7(1):227-229.

18.

Glauert AM Practical Methods in Electron Microscopy. Amsterdam: North-Holland Pub Co; 1998.

19.

Bevers EM , Comfurius P. , Dekkers DW , Zwaal RF Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta. 1999;1439(3):317-330.

20.

Zhao M. , Li Z. , Bugenhagen S. 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med. 2008;49(8):1345-1352.

21.

Esmon CT The protein C pathway. Chest. 2003;124(3 suppl): 26S-32S.

22.

Esmon NL , Safa O. , Smirnov MD , Esmon CT Antiphospholipid antibodies and the protein C pathway. J Autoimmun . 2000; 15(2):221-225.

23.

Gautam M. , Gojova A. , Barakat AI Flow-activated ion channels in vascular endothelium. Cell Biochem Biophys. 2006;46(3):277-284.

24.

Chien S. Effects of disturbed flow on endothelial cells. Ann Biomed Eng. 2008;36(4):554-562.

25.

Garin G. , Berk BC Flow-mediated signaling modulates endothelial cell phenotype. Endothelium. 2006;13(6):375-384.

26.

Fujiwara K. Platelet endothelial cell adhesion molecule-1 and mechanotransduction in vascular endothelial cells. J Intern Med. 2006;259(4):373-380.

27.

Tzima E. Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ Res. 2006;98(2): 176-185.

28.

Weiler-Guettler H. , Aird WC , Husain M. , Rayburn H. , Rosenberg RD Targeting of transgene expression to the vascular endothelium of mice by homologous recombination at the thrombomodulin locus . Circ Res. 1996;78(2):180-187.

29.

Laszik Z. , Mitro A. , Taylor FB Jr , Ferrell G. , Esmon CT Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation. 1997;96(10):3633-3640.